The U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) on October 7, ...

Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo ...

Boehringer Ingelheim, a global leader in animal health, today announced the availability of the new Quarterable Snap-Tab design for PREVICOX® (firocoxib) Chewable Tablets, following approval from the ...

Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...

Your liver already cleans itself. That is its job, and it does it for free. Dr. Oz makes the case for skipping the 100 dollar ...

HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing ...

In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with ...

Despite a nearly 600% surge in adolescent GLP-1 prescriptions, the WHO says they may pose critical safety risks to growing bodies.

USDA Food Safety Under Secretary Dr. Mindy Brashears explains efforts to expand small processor access, modernize inspection, and improve competition.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with ...

VivoSim Labs, Inc. ( VIVS ), a provider of next-generation New Approach Methodologies (NAM) 3D human cellular models for preclinical safety, highlighted the FDA's updated regulations allowing greater ...

An estimated 5 million people are using compounded GLP-1s in the U.S., according to a Gallup poll released in July; of the 11 ...